+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

White coat hypertension in NIDDM patients with and without incipient and overt diabetic nephropathy



White coat hypertension in NIDDM patients with and without incipient and overt diabetic nephropathy



Diabetes Care 20(5): 859-863



Early data have suggested a high prevalence of white coat hypertension (approximately 50%) in NIDDM patients. To study this phenomenon further, we determined the prevalence of white coat hypertension in NIDDM patients with normo- or microalbuminuria or with diabetic nephropathy. Three groups of hypertensive NIDDM patients (repeated clinic blood pressure > 140/90 mmHg or antihypertensive treatment) attending the Steno Diabetes Center were investigated in a cross-sectional study. Group 1 had normoalbuminuria (a urinary albumin excretion [UAE] rate < 30 mg/24 h, n = 30, age 61 +/- 7 [mean +/- SD] years, 20 men), group 2 had microalbuminuria (UAE rate 30-300 mg/24 h, n = 51, age 55 +/- 7 years, 35 men), and group 3 had diabetic nephropathy (UAE rate > 300 mg/24 h, n = 47, 62 +/- 7 years, 36 men). If given, all previous antihypertensive medication was withdrawn at least 2 weeks before the study (48%). The prevalence of white coat hypertension (clinic hypertension with normal blood pressure values at home) was determined by comparison of clinic blood pressure (Hawksley Random sphygmomanometer) and the ambulatory daytime (7:00 A.M. to 11:00 P.M.) blood pressure (A&D TM2420). By applying established criteria, white coat hypertension was confirmed if daytime blood pressure was < 135/85 mmHg. The clinic blood pressure was 155/86 (SE 3/2) mmHg, 156/89 (2/1) mmHg, and 171/90 (3/2) mmHg in group 1, 2, and 3, respectively (P < 0.05 comparing group 3 with groups 1 and 2). The prevalence of white coat hypertension was significantly higher in group 1 as compared with groups 2 and 3, 23% (95% CI 10-42) vs. 8% (2-19) and 9% (2-20) (P < 0.05), with no difference between the latter two groups. The prevalence of white coat hypertension in normoalbuminuric NIDDM patients resembles that observed in nondiabetic subjects with essential hypertension, whereas the prevalence is significantly lower in NIDDM patients with incipient or overt diabetic nephropathy, suggesting a difference between primary and secondary hypertension.

(PDF emailed within 0-6 h: $19.90)

Accession: 047968892

Download citation: RISBibTeXText

PMID: 9135956

DOI: 10.2337/diacare.20.5.859


Related references

Incipient and overt diabetic nephropathy in African Americans with NIDDM. Diabetes Care 17(4): 297-304, 1994

The telmisartan renoprotective study from incipient nephropathy to overt nephropathy--rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study. Journal of International Medical Research 33(6): 677-686, 2005

Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy. Diabetes Care 29(5): 1024-1030, 2006

Monitoring Kidney Function in Type 2 Diabetic Patients With Incipient and Overt Diabetic Nephropathy. Diabetes Care 29(5): 1024-1030, 2006

White coat hypertension in type 1 diabetic patients without nephropathy. American Journal of Hypertension 13(5 Part 1): 560-563, 2000

Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care 25(5): 859-864, 2002

Bone metabolism in IDDM patients with incipient and overt diabetic nephropathy. Diabetologia 40(SUPPL 1): A579, 1997

Risk factors for development of incipient and overt diabetic nephropathy in IDDM patients. Journal of the American Society of Nephrology 4(3): 308, 1993

Elevated serum level of soluble VCAM-1 in NIDDM patients with overt diabetic nephropathy. Nephrology Dialysis Transplantation 17(Abstracts Suppl. 1): 221, 2002

Surface charge of red blood cells in insulin-dependent diabetic patients with incipient and overt nephropathy. Diabetic Medicine 4(5): 431-433, 1987

Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy. Diabetologia 48(1): 198-202, 2004

Effects of lisinopril and nifedipine on the progression to overt proteinuria in normotensive insulin dependent diabetic patients with incipient nephropathy. Diabetologia 40(SUPPL 1): A545, 1997

Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 314(7083): 783-788, 1997

Benefits and cost of antihypertensive treatment in incipient and overt diabetic nephropathy. Journal of Hypertension. Suppl. 16(1): S99-101, 1998

The course of incipient and overt diabetic nephropathy the perspective of insulin pump treatment. Mogensen, C E (Ed ) Topics in Renal Medicine: The Kidney And Hypertension in Diabetes Mellitus Xxi+423p Kluwer Academic Publishers: Dordrecht, Netherlands; Boston, Massachusetts, Usa Illus 199-204, 1988